- Home
- FLR vs ORKA Comparison
FLR vs ORKA Comparison
Compare FLR & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLR | ORKA |
|---|---|---|
| Founded | 1912 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 7.1B |
| IPO Year | 2006 | 1997 |
Fundamental Metrics
Financial Performance| Metric | FLR | ORKA |
|---|---|---|
| Price | $53.06 | $89.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $53.50 | ★ $92.50 |
| AVG Volume (30 Days) | ★ 1.9M | 736.2K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.89 | N/A |
| Revenue | ★ $15,503,000,000.00 | N/A |
| Revenue This Year | $6.56 | N/A |
| Revenue Next Year | $7.10 | N/A |
| P/E Ratio | $28.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $39.33 | $14.89 |
| 52 Week High | $58.35 | $115.52 |
Technical Indicators
Market Signals| Indicator | FLR | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.13 |
| Support Level | N/A | $83.25 |
| Resistance Level | N/A | $97.02 |
| Average True Range (ATR) | 0.00 | 4.32 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 0.00 | 56.57 |
Price Performance
Historical ComparisonAbout FLR Fluor Corporation
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $15.5 billion in revenue in 2025.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.